Catalyst Pharmaceuticals initiated with an Outperform at Baird
Baird analyst Joel Beatty last night initiated coverage of Catalyst Pharmaceuticals (CPRX) with an Outperform rating and $28 price target ...
Baird starts Catalyst Pharma with Outperform, $28 target
Baird initiated coverage on Catalyst Pharmaceutical Partners (NASDAQ:CPRX) with an Outperform rating and set a price target ...
pharmaphorum5d
Price deal opens door to NHS use of Santhera DMD drug
Santhera's Duchenne muscular dystrophy (DMD) therapy Agamree has been cleared for NHS use after a confidential pricing agreement. The deal means that Agamree (vamorolone) will be available to ...
Investor's Business Daily on MSN6d
This Drug Stock Sits On A Strong Earnings Foundation As It Tests New Entry
This pharma stock has made strong gains over the past 12 months thanks to its strong earnings. Now it is testing a fresh buy ...
pharmaphorum5d
Santhera preps UK Duchenne drug launch after NICE says yes
The announcement follows finalised recommendations this week that backed Agamree (vamorolone) as a treatment for patients aged four and over with DMD from the National Institute for Health and ...
Essential Pharma and Clinigen Expand Collaboration to Improve Patient Access in JAPAC
Agreement drives continued patient access to four important therapies in Japan and Korea Strengthens Essential Pharma and Clinigen's combined market presence in the JAPAC region Egham, UK - 6th ...
Palantir upgraded, Nio downgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors ...